Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Rituximab

First Posted Date: 2006-01-11

Last Posted Date: 2019-05-23

Lead Sponsor: German CLL Study Group

Target Recruit Count: 825

Registration Number: NCT00275054

Locations: 🇦🇹
Universitaetsklinik fuer Innere Medizin I, Vienna, Austria
🇫🇷
CHU Poitiers, Poitiers, France
🇩🇪
St. Hedwig Krankenhaus, Berlin, Germany

and more 84 locations

Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine

First Posted Date: 2005-12-07

Last Posted Date: 2020-02-20

Lead Sponsor: German CLL Study Group

Target Recruit Count: 877

Registration Number: NCT00262782

Locations: 🇩🇪
Internistische Praxis - Neuenkirchen, Neuenkirchen, Germany
🇩🇪
Klinikum St. Marien, Amberg, Germany
🇩🇪
Internistische Praxis - Arnstadt, Arnstadt, Germany

and more 112 locations

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2005-12-07

Last Posted Date: 2013-06-06

Lead Sponsor: University of Rochester

Target Recruit Count: 35

Registration Number: NCT00262886

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Chlorambucil
Drug: Fludarabine

First Posted Date: 2005-12-07

Last Posted Date: 2019-05-23

Lead Sponsor: German CLL Study Group

Target Recruit Count: 206

Registration Number: NCT00262795

Locations: 🇩🇪
Onkologische Schwerpunktpraxis, Cottbus, Germany
🇦🇹
Hanuschkrankenhaus, Vienna, Austria
🇩🇪
Saint Josef - Hospital Bochum, Bochum, Germany

and more 85 locations

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Phase 2

Completed

Conditions: Fanconi Anemia

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: busulfan
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: methylprednisolone
Biological: Hematopoietic stem cell transplantation

First Posted Date: 2005-11-24

Last Posted Date: 2021-12-02

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 14

Registration Number: NCT00258427

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Not Applicable

Terminated

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: graft-versus-tumor induction therapy
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy

First Posted Date: 2005-11-21

Last Posted Date: 2016-11-03

Lead Sponsor: University of Rochester

Target Recruit Count: 16

Registration Number: NCT00255684

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2005-11-21

Last Posted Date: 2010-03-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 60

Registration Number: NCT00255710

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mitoxantrone
Drug: Rituximab
Drug: Filgrastim

First Posted Date: 2005-11-16

Last Posted Date: 2019-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00254410

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2005-11-15

Last Posted Date: 2012-06-01

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00253513

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients

Phase 3

Completed

Conditions: B-Cell Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Pentostatin

First Posted Date: 2005-11-15

Last Posted Date: 2016-11-03

Lead Sponsor: US Oncology Research

Target Recruit Count: 184

Registration Number: NCT00254163

Locations: 🇺🇸
New York Oncology Hematology, PC, Albany, New York, United States
🇺🇸
St Joseph Oncology, Inc, St Joseph, Missouri, United States
🇺🇸
Alliance Hematology Oncology PA, Westminster, Maryland, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy